MANNKIND CORP Finance Lease, Liability, Noncurrent
MANNKIND CORP (MNKD) had Finance Lease, Liability, Noncurrent of $171.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:FinanceLeaseLiabilityNoncurrent · last filed 2024-11-07
- 2024-09-30: Finance Lease, Liability, Noncurrent $171.00K.
- 2024-06-30: Finance Lease, Liability, Noncurrent $184.00K.
- 2024-03-31: Finance Lease, Liability, Noncurrent $94.21M.
- 2023-12-31: Finance Lease, Liability, Noncurrent $94.32M.
| Period end | Finance Lease, Liability, Noncurrent | Finance Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2024-09-30 | $171.00K 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $184.00K 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $94.21M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $94.32M 10-Q · filed 2024-05-08 | |
| 2023-09-30 | $94.38M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $94.39M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $94.44M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $94.51M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $94.48M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $94.45M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $93.46M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $93.53M 10-K · filed 2023-02-23 | |
| 2021-11-30 | $94.50M 10-K · filed 2023-02-23 | $93.50M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |